Tags

Type your tag names separated by a space and hit enter

Regular use of aspirin and prostate cancer risk (United States).
Cancer Causes Control 2006; 17(3):251-6CC

Abstract

It has been hypothesized that aspirin and other nonsteroidal anti-inflammatory drugs can decrease the risk of developing prostate and other cancers, although observational studies have not been very conclusive. The current study examined the effects of regular aspirin use on prostate cancer risk in 1,029 patients with primary, incident cancer of the prostate and 1,029 hospital controls frequency-matched to cases by 5-year age group and period of questionnaire completion. Patients who reported use of aspirin for at least once a week for at least 6 months were classified as regular users, with others classified as non-users. Results indicate that regular aspirin use may not be associated with decreased prostate cancer risk [odds ratio (OR) 1.05, 95% confidence interval (CI) 0.89-1.25], frequency of use (OR for at least seven/week 0.91, 95% CI 0.73-1.13), duration of use (OR for at least 10 years of use 1.17 95% CI 0.93-1.46) or tablet years (defined as tablets per day x years of use). A similar lack of association was observed when analyses were performed examining stage of the cancer. These data suggest that aspirin use may not be associated with reduced risk of prostate cancer.

Authors+Show Affiliations

Department of Epidemiology, Roswell Park Cancer Institute, A-316 Carlton House, Buffalo, NY 14263, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16489532

Citation

Menezes, Ravi J., et al. "Regular Use of Aspirin and Prostate Cancer Risk (United States)." Cancer Causes & Control : CCC, vol. 17, no. 3, 2006, pp. 251-6.
Menezes RJ, Swede H, Niles R, et al. Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control. 2006;17(3):251-6.
Menezes, R. J., Swede, H., Niles, R., & Moysich, K. B. (2006). Regular use of aspirin and prostate cancer risk (United States). Cancer Causes & Control : CCC, 17(3), pp. 251-6.
Menezes RJ, et al. Regular Use of Aspirin and Prostate Cancer Risk (United States). Cancer Causes Control. 2006;17(3):251-6. PubMed PMID: 16489532.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Regular use of aspirin and prostate cancer risk (United States). AU - Menezes,Ravi J, AU - Swede,Helen, AU - Niles,Robert, AU - Moysich,Kirsten B, PY - 2005/06/15/received PY - 2005/09/12/accepted PY - 2006/2/21/pubmed PY - 2006/9/30/medline PY - 2006/2/21/entrez SP - 251 EP - 6 JF - Cancer causes & control : CCC JO - Cancer Causes Control VL - 17 IS - 3 N2 - It has been hypothesized that aspirin and other nonsteroidal anti-inflammatory drugs can decrease the risk of developing prostate and other cancers, although observational studies have not been very conclusive. The current study examined the effects of regular aspirin use on prostate cancer risk in 1,029 patients with primary, incident cancer of the prostate and 1,029 hospital controls frequency-matched to cases by 5-year age group and period of questionnaire completion. Patients who reported use of aspirin for at least once a week for at least 6 months were classified as regular users, with others classified as non-users. Results indicate that regular aspirin use may not be associated with decreased prostate cancer risk [odds ratio (OR) 1.05, 95% confidence interval (CI) 0.89-1.25], frequency of use (OR for at least seven/week 0.91, 95% CI 0.73-1.13), duration of use (OR for at least 10 years of use 1.17 95% CI 0.93-1.46) or tablet years (defined as tablets per day x years of use). A similar lack of association was observed when analyses were performed examining stage of the cancer. These data suggest that aspirin use may not be associated with reduced risk of prostate cancer. SN - 0957-5243 UR - https://www.unboundmedicine.com/medline/citation/16489532/Regular_use_of_aspirin_and_prostate_cancer_risk__United_States__ L2 - https://doi.org/10.1007/s10552-005-0450-z DB - PRIME DP - Unbound Medicine ER -